Influence of anti-osteoporosis treatments on the incidence of COVID-19 in patients with non-inflammatory rheumatic conditions
Josep Blanch-Rubió, Natalia Soldevila-Domenech, Laura Tío, Jone Llorente-Onaindia, Manuel Ciria-Recasens, Luciano Polino, Alba Gurt, Rafael De La Torre, Rafael Maldonado, Jordi Monfort, Covidmar Study
INTRODUCTION Infections by SARS-CoV-2, a novel coronavirus that emerged in China in late 2019 [1], and the disease that it causes, COVID-19, became a global pandemic on March 11 th , 2020 [2]. By July19 th , 2020, COVID-19 had infected 14,348,475 people and caused 603,167 deaths worldwide [3].
Abbreviations ARBs: angiotensin II receptor blockers; ACE: angiotensin-converting-enzyme; CI: confidence interval; COVID-19: Coronavirus disease 19; CV: cardiovascular; NSAIDs: non-steroidal anti-inflammatory drugs; SERMs: selective estrogen receptor modulators; SSRIs: serotonin reuptake inhibitors.
AUTHOR CONTRIBUTIONS J.B.R. was involved in conceptualizing the research idea, creating the research design, making the final interpretation of the statistical analyses, and writing the first draft and revision of the manuscript. N.S.D. participated in selection of statistical tests/analyses, performed the statistical analyses, computations and related computer work, and participated in writing the manuscript. L.T. was involved in conceptualizing the research idea, setting-up the research design, making the primary interpretation of the statistical analyses and participated in writing the manuscript. J.L.O. was involved in conceptualizing the research idea, setting-up the research design, making the primary interpretation of the statistical analyses and participated in writing the manuscript. M.C.R., L.P, and A.G. were responsible for patient cohort data collection. R.D.L.T. contributed to the statistical analyses and revised the manuscript. R.M. and J.M. were involved in conceptualizing the research idea, creating the research design, making the final interpretation of the statistical analysis, and writing the first draft and revision of the manuscript.
CONFLICTS OF INTEREST..
References
Abu-Rish, Mansour, Mansour, Dahabiyeh, Aleidi et al., Pregabalin inhibits in vivo and in vitro cytokine secretion and attenuates spleen inflammation in Lipopolysaccharide/Concanavalin Ainduced murine models of inflammation, Sci Rep,
doi:10.1038/s41598-020-61006-1Aelis, Janus, Upjohn, Gedeon, MCR has received grants or consulting
Awwad, El-Ganainy, Elmallah, Khedr, Khattab et al., Assessment of pregabalininduced cardiotoxicity in rats: mechanistic role of angiotensin 1-7, Cardiovasc Toxicol,
doi:10.1007/s12012-019-09553-6Bergman, Nordström, Hommel, Kivipelto, Nordström, Bisphosphonates and mortality: confounding in observational studies?, Osteoporos Int,
doi:10.1007/s00198-019-05097-1Brufsky, Marti, Nasrazadani, Lotze, Boning up: amino-bisphophonates as immunostimulants and endosomal disruptors of dendritic cell in SARS-CoV-2 infection, J Transl Med,
doi:10.1186/s12967-020-02433-6Brunton, Goodman and Gilman's: The Pharmacological Basis of Therapeutics
Buschmann, Hernandez, Use of compounds binding to the sigma receptor for the treatment of metabolic syndrome, Spain
Cappellini, Brivio, Casati, Cavallero, Contro et al., Low levels of total and ionized calcium in blood of COVID-19 patients, Clin Chem Lab Med,
doi:10.1515/cclm-2020-0611Colón-Emeric, Mesenbrink, Lyles, Pieper, Boonen et al., Potential mediators of the mortality reduction with zoledronic acid after hip fracture, J Bone Miner Res,
doi:10.1359/jbmr.090704Coxon, Helfrich, Van't Hof, Sebti, Ralston et al., Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298, J Bone Miner Res,
doi:10.1359/jbmr.2000.15.8.1467Cremers, Drake, Ebetino, Bilezikian, Russell, Pharmacology of bisphosphonates, Br J Clin Pharmacol,
doi:10.1111/bcp.13867El-Kurdi, Khatua, Rood, Snozek, Cartin-Ceba et al., Lipotoxicity in COVID-19 Study Group. Mortality from coronavirus disease 2019 increases with unsaturated fat and may be reduced by early calcium and albumin supplementation, Gastroenterology,
doi:10.1053/j.gastro.2020.05.057Gianfrancesco, Hyrich, Al-Adely, Carmona, Danila et al., Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physicianreported registry, Ann Rheum Dis,
doi:10.1136/annrheumdis-2020-217871Gordon, Jang, Bouhaddou, Xu, Obernier et al., A SARS-CoV-2 protein interaction map reveals targets for drug repurposing, Nature,
doi:10.1038/s41586-020-2286-9Haberman, Axelrad, Chen, Castillo, Yan et al., Covid-19 in immune-mediated inflammatory diseases -case series from New York, N Engl J Med,
doi:10.1056/NEJMc2009567Kanis, Cooper, Rizzoli, Reginster, Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF). Executive summary of the European guidance for the diagnosis and management of osteoporosis in postmenopausal women, Calcif Tissue Int,
doi:10.1007/s00223-018-00512-xKhan, Fabbri, Stewart, Robinson, Smyth et al., A systematic review of Anakinra, Tocilizumab, Sarilumab and Siltuximab for coronavirusrelated infections,
doi:10.1101/2020.04.23.20076612Kobayashi-Sakamoto, Tamai, Kiyoura, Beyond bone remodeling-emerging functions of osteoprotegerin in host defense and microbial infection, Integr Mol Med,
doi:10.15761/IMM.1000173Landewé, Machado, Kroon, Bijlsma, Burmester et al., EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2, Ann Rheum Dis,
doi:10.1136/annrheumdis-2020-217877Lee, Vivithanaporn, Siemieniuk, Krentz, Maingat et al., Clinical outcomes and immune benefits of anti-epileptic drug therapy in HIV/AIDS, BMC Neurol,
doi:10.1186/1471-2377-10-44Lyles, Colón-Emeric, Magaziner, Adachi, Pieper et al., Recurrent Fracture Trial. Zoledronic acid and clinical fractures and mortality after hip fracture, N Engl J Med,
doi:10.1056/NEJMoa074941Martino, Rocchi, Escelsior, Fornaro, Immunomodulation mechanism of antidepressants: interactions between serotonin/norepinephrine balance and Th1/Th2 balance, Curr Neuropharmacol,
doi:10.2174/157015912800604542Merad, Martin, Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages, Nat Rev Immunol,
doi:10.1038/s41577-020-0331-4Michelena, Borrell, López-Corbeto, López-Lasanta, Moreno et al., Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic diseasemodifying anti-rheumatic drugs, Semin Arthritis Rheum,
doi:10.1016/j.semarthrit.2020.05.001Okamoto, Jiang, Kawamura, Shingyoji, Tada et al., Zoledronic acid induces apoptosis and s-phase arrest in mesothelioma through inhibiting rab family proteins and topoisomerase II actions, Cell Death Dis,
doi:10.1038/cddis.2014.475Ortuño, Robinson, Subramanyam, Paone, Huang et al., Serotonin-reuptake inhibitors act centrally to cause bone loss in mice by counteracting a local antiresorptive effect, Nat Med,
doi:10.1038/nm.4166Poccia, Agrati, Castilletti, Bordi, Gioia et al., Anti-severe acute respiratory syndrome coronavirus immune responses: the role played by V gamma 9V delta 2 T cells, J Infect Dis,
doi:10.1086/502975Santos, Sampaio, Alzamora, Motta-Santos, Alenina et al., The ACE2/Angiotensin-(1-7)/MAS axis of the reninangiotensin system: focus on angiotensin-(1-7), Physiol Rev,
doi:10.1152/physrev.00023.2016Taylor, Angelotti, Fauman, Pharmacology and mechanism of action of pregabalin: the calcium channel alpha2-delta (alpha2-delta) subunit as a target for antiepileptic drug discovery, Epilepsy Res,
doi:10.1016/j.eplepsyres.2006.09.008Vaeth, Eckstein, Shaw, Kozhaya, Yang et al., Store-operated Ca(2+) entry in follicular T cells controls humoral immune responses and autoimmunity, Immunity,
doi:10.1016/j.immuni.2016.04.013Wasserstein, Schirm, Lazar, Moving to a World Beyond, Am Stat [Internet
Yu, Tsourdi, Clarke, Bauer, Drake, Osteoporosis management in the era of COVID-19, J Bone Miner Res,
doi:10.1002/jbmr.4049Zhang, Yu, Pan, Jiang, ACEI/ARB use and risk of infection or severity or mortality of COVID-19: A systematic review and meta-analysis, Pharmacol Res,
doi:10.1016/j.phrs.2020.104927DOI record:
{
"DOI": "10.18632/aging.104117",
"ISSN": [
"1945-4589"
],
"URL": "http://dx.doi.org/10.18632/aging.104117",
"alternative-id": [
"104117"
],
"author": [
{
"affiliation": [],
"family": "Blanch-Rubió",
"given": "Josep",
"sequence": "first"
},
{
"affiliation": [],
"family": "Soldevila-Domenech",
"given": "Natalia",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Tío",
"given": "Laura",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Llorente-Onaindia",
"given": "Jone",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Ciria-Recasens",
"given": "Manuel",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Polino",
"given": "Luciano",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Gurt",
"given": "Alba",
"sequence": "additional"
},
{
"affiliation": [],
"family": "de la Torre",
"given": "Rafael",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Maldonado",
"given": "Rafael",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Monfort",
"given": "Jordi",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Group",
"given": "the Covidmar Study",
"sequence": "additional"
}
],
"container-title": "Aging",
"container-title-short": "aging",
"content-domain": {
"crossmark-restriction": false,
"domain": []
},
"created": {
"date-parts": [
[
2020,
10,
20
]
],
"date-time": "2020-10-20T20:18:53Z",
"timestamp": 1603225133000
},
"deposited": {
"date-parts": [
[
2020,
11,
5
]
],
"date-time": "2020-11-05T22:22:56Z",
"timestamp": 1604614976000
},
"indexed": {
"date-parts": [
[
2024,
3,
24
]
],
"date-time": "2024-03-24T07:37:16Z",
"timestamp": 1711265836733
},
"is-referenced-by-count": 36,
"issue": "20",
"issued": {
"date-parts": [
[
2020,
10,
20
]
]
},
"journal-issue": {
"issue": "20",
"published-online": {
"date-parts": [
[
2020,
10,
31
]
]
}
},
"language": "en",
"link": [
{
"URL": "http://www.aging-us.com/article/104117/text?_escaped_fragment_=",
"content-type": "unspecified",
"content-version": "vor",
"intended-application": "similarity-checking"
}
],
"member": "7892",
"original-title": [],
"page": "19923-19937",
"prefix": "10.18632",
"published": {
"date-parts": [
[
2020,
10,
20
]
]
},
"published-online": {
"date-parts": [
[
2020,
10,
20
]
]
},
"publisher": "Impact Journals, LLC",
"reference-count": 0,
"references-count": 0,
"relation": {},
"resource": {
"primary": {
"URL": "http://www.aging-us.com/article/104117/text"
}
},
"score": 1,
"short-title": [],
"source": "Crossref",
"subject": [
"Cell Biology",
"Aging"
],
"subtitle": [],
"title": "Influence of anti-osteoporosis treatments on the incidence of COVID-19 in patients with non-inflammatory rheumatic conditions",
"type": "journal-article",
"volume": "12"
}
